|12 Months Ended|
Dec. 31, 2022
Note 14 — Geographic information
Operations by geographic area
Revenue represents recognized income from the Astellas Collaboration Agreement, the GNE Collaboration and License Agreement and the GSK Collaboration and License Agreement. All revenue was derived in the United Kingdom.
Long-lived assets (excluding intangibles, deferred tax and financial instruments) were located as follows (in thousands):
During the year ended December 31, 2022, 21%, 50% and 29% of the Company’s revenues were generated from Astellas, Genentech and GSK, respectively.
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
No definition available.